Precigen, Inc. Common Stock

PGEN trades with 20.59% short interest—meaningfully elevated for a biotech name—while RSI sits neutrally at 54.0, suggesting neither oversold nor overbought conditions. The stock's $1.6B market cap reflects modest scale, and the absence of a P/E ratio signals ongoing losses, typical for early-stage pharma. Trading below its 52-week high leaves room for sentiment recovery, yet the substantial short position hints at skepticism among sophisticated traders. This setup creates potential squeeze dynamics if positive catalysts emerge, though the lack of profitability underscores execution risk.